ARTICLE SUMMARY:
Abbott’s proposed acquisition of Alere highlights an area in diagnostics that is ripe for innovation and growth. New technologies promise to overcome hurdles associated with PCR in producing rapid, cost-effective point-of-care molecular diagnostic systems.
Abbott Laboratories Inc.’s interest in acquiring Alere Inc. for $5.8 billion indicates just how attractive the near-patient molecular point-of-care testing (POCT) market is becoming, and change POCT market dynamics as the second large, diversified player to step in.
